Novel Antibiotics from Marine Invertebrate Microbes
Novel Antibiotics from Marine Invertebrate Microbes
批准号:
9407904
负责人:
Amy Lynn Spoering
金额:
$28.62万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-09 至 2019-07-31
关键词:
AddressAgarAnimal SourcesAnimalsAnti-Bacterial AgentsAntibioticsAntimicrobial ResistanceBackBacteriaBiologicalBiological AssayCellsChemicalsCollaborationsCollectionComplexDevelopmentDevicesDiffuseDiffusionEnvironmentEscherichia coliFractionationFundingFutureGenesGoalsGrowthGrowth FactorIn SituIncubatedInvertebratesLaboratoriesMarine InvertebratesMarinesMass Spectrum AnalysisMembraneMethicillin ResistanceMethodologyMethodsMicrobeNew EnglandNutrientOrganismPhasePhylogenetic AnalysisPoriferaPropertyPublic HealthRecombinant DNAResearchResistanceResolutionResourcesSoilSourceStaphylococcus aureusSterilitySurfaceTechniquesTechnologyTestingTherapeuticToxic effectUnited States National Institutes of HealthVancomycin resistant enterococcusVariantWorkantimicrobialaquariumbasecell growthcombatcoralcytotoxicitydesignflexibilityinnovationmicrobialmicroorganismmulti-drug resistant pathogennovelpathogenpreventscreeningsuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
The rise of multi-drug resistant pathogens, particularly ESKAPE pathogens, is a major public health
concern. One effective countermeasure against such pathogens is novel antibiotics, but the rate of antibiotic
discovery has been in steady decline. One particularly promising source of novel antibiotics is microbial species
because most of them have never been cultivated or explored. This is especially true about marine species,
specifically microbes living in association with invertebrates: such symbioses are known producers of bioactive
compounds, these compounds likely originate from associated microbes, but only few of them are available in
culture. We have designed and developed several proprietary technology platforms to grow and isolate such
“uncultivable” microorganisms.
These platforms are based on a simple idea: strains that do not grow in the lab can be grown in their
natural environments if placed into small diffusion chambers. Cells inside such chambers, if returned back to the
original environment, will be naturally fed by nutrients and growth factors diffusing through semipermeable
membranes. This approach has resulted in the discovery of several new compounds, including teixobactin, an
exciting new class of antibiotic that is active against resistant pathogens. This general approach can be used to
grow invertebrate-associated, previously uncultivated microorganisms as well. For this project, we designed
diffusion chambers that are flexible and can assume the topography of the animal, thus providing an immediate
contact with the host – and the compounds it produces. In preliminary studies, we validated this general approach
by growing a diverse collection of novel microorganisms showing antimicrobial activities. Here we will capitalize
on these advances and achieve the following Specific Aims.
Aim 1. Developing a method to grow and isolate novel microbial species living in association with marine
invertebrates. We will use our new method to isolate 5000 microorganisms from 4 invertebrate species.
Aim 2. Screening for antimicrobial activity. We will ferment the strains from Aim 1 and screen them against
a panel of Gram-negative and Gram-positive pathogens, prioritizing 100 strains for chemical dereplication.
Aim 3. Chemical dereplication of antimicrobial compounds. Using traditional separation methodologies,
bioassay-guided fractionation, and high-resolution mass spectrometry, we will identify extracts with novel
antimicrobial compounds and isolate these compounds into pure substances. We aim at discovering 1-3 novel
compounds with low toxicity and a good spectrum of activity and potency.
The end products of this project, an innovative cultivation platform, a large collection of novel marine
microorganisms, and a selection of antimicrobials they produce, will set the stage for development of novel
antibiotics in the future Phase II application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Antifungal discovery from previously uncultivated bacteria
-
批准号:10693593
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2023
-
负责人:Amy Lynn Spoering
-
依托单位:
Microbial symbionts of marine invertebrates for antibiotic discovery
-
批准号:8978558
-
项目类别:
-
资助金额:$22.44万
-
财政年份:2015
-
负责人:Amy Lynn Spoering
-
依托单位:
Drug Discovery from Slow Growing and Rare Microbial Species
-
批准号:8078947
-
项目类别:
-
资助金额:$29.96万
-
财政年份:2010
-
负责人:Amy Lynn Spoering
-
依托单位:
High throughput antibiotic discovery from the uncultivated microbial majority.
-
批准号:7799539
-
项目类别:
-
资助金额:$29.81万
-
财政年份:2010
-
负责人:Amy Lynn Spoering
-
依托单位:
Drug Discovery from Slow Growing and Rare Microbial Species
-
批准号:8769138
-
项目类别:
-
资助金额:$98.16万
-
财政年份:2010
-
负责人:Amy Lynn Spoering
-
依托单位:
Drug Discovery from Slow Growing and Rare Microbial Species
-
批准号:8594217
-
项目类别:
-
资助金额:$98.65万
-
财政年份:2010
-
负责人:Amy Lynn Spoering
-
依托单位:
Drug Discovery from Slow Growing and Rare Microbial Species
-
批准号:8455539
-
项目类别:
-
资助金额:$99.97万
-
财政年份:2010
-
负责人:Amy Lynn Spoering
-
依托单位:
High throughput antibiotic discovery from the uncultivated microbial majority.
-
批准号:8039188
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2010
-
负责人:Amy Lynn Spoering
-
依托单位:
Drug Discovery from Slow Growing and Rare Microbial Species
-
批准号:8000469
-
项目类别:
-
资助金额:$29.94万
-
财政年份:2010
-
负责人:Amy Lynn Spoering
-
依托单位:
国内基金
海外基金
Cd(II)在NH2-Agar/PSS双网络水凝胶上的吸附行为及资源化工艺研究
-
批准号:51708204
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2017
-
负责人:周贵寅
-
依托单位: